Showing 4751-4760 of 5771 results for "".
- Novartis Implementing Programs to Assist Optometrists During COVID-19https://modernod.com/news/novartis-implementing-programs-to-assist-optometrists-during-covid-19/2477609/Novartis announced that it is implementing the following to ensure optometrists are well-equipped to provide care for patients during the COVID-19 pandemic: Strengthening the online, self-service sample website –
- White House Details Guidelines for Businesses, Hospitals to Get Back to ‘Normality’https://modernod.com/news/white-house-details-guidelines-for-businesses-hospitals-to-get-back-to-normality/2477606/The U.S. will begin following a phased-in approach to begin reopening the economy in the wake of the COVID-19 crisis, the White House Coroanavirus Task Force announced on Thursday evening, as
- FDA Grants Priority Review Approval For Regeneron’s REGN-EB3 to Treat Ebolahttps://modernod.com/news/fda-crants-for-priority-review-approval-for-regenerons-regn-eb3-to-treat-ebola/2477599/Regeneron Pharmaceuticals announced that the FDA has accepted for priority review a new biologics license application (BLA) for REGN-EB3, an investigational triple antibody cocktail treatment for Ebola virus infection. The target action date for the FDA decision is October 25, 2020.
- Call for Nominations Issued for the 2020 Bonnie Strickland Champion for Children’s Vision Awardhttps://modernod.com/news/call-for-nominations-issued-for-the-2020-bonnie-strickland-champion-for-childrens-vision-award/2477595/The National Center for Children’s Vision and Eye Health at Prevent Blindness (NCCVEH) has issued the call for nominations for the sixth annual “Bonnie Strickland Champion for Children’
- TearClear Appoints Robert J. Dempsey Chief Executive Officerhttps://modernod.com/news/tearclear-appoints-robert-j-dempsey-chief-executive-officer/2477596/TearClear announced the appointment of Robert J. Dempsey as Chief Executive Officer. TearClear is the only pharmaceutical company to administer preservative free eye drops to the ocular surface, that are preserved safely prior to dosing, according to a company news release. <
- Eyenuk Successfully Fulfills Contract for Artificial Intelligence Grading of Retinal Imageshttps://modernod.com/news/eyenuk-successfully-fulfills-contract-for-artificial-intelligence-grading-of-retinal-images/2477588/Eyenuk announced that it has successfully fulfilled the contract awarded by Public Health England (PHE) to use Eyenuk’s EyeArt AI Eye Screening System to grade 60,000 patient image sets from 6 different National Health Service (NHS) Diabetic Eye Screening Programs in England. The UK has be
- Leo Lens Pharma Appoints Dan Myers CEOhttps://modernod.com/news/leo-lens-pharma-appoints-dan-myers-ceo/2477589/Leo Lens Pharma has announced the appointment of Dan Myers as Chief Executive Officer. Prior to joining Leo Lens, Mr. Myers was the co-founder and Chief Executive Officer of Alimera Sciences, where he continues to serve as chairman of the Board of Directors. Before founding Alimera, Mr. Myers was
- HealthVerity Patient Confidence Index Aims to Become Bellwether Measure of Impact to Non-COVID-19 Patients and Physicianshttps://modernod.com/news/healthverity-patient-confidence-index-aims-to-become-bellwether-measure-of-impact-to-non-covid-19-patients-and-physicians/2477590/HealthVerity, a provider of privacy-protected data exchange for pharmaceutical manufacturers and insurers, announced the launch of the HealthVerity Patient Confidence Index, or HVPCI, and reported the first national benchmark score of 68. Indexed against a pre-pandemic score of 100, this level is
- Nidek Launches the CP-9 Chart Projectorhttps://modernod.com/news/nidek-launches-the-cp-9-chart-projector/2477580/Nidek has announced the launch of the CP-9 Chart Projector, designed to provide a brighter and clearer chart display with a white LED. The long-life light source achieves high cost efficiency for daily examination, a
- AstraZeneca to Study BTK Inhibitor Calquence as Treatment for Cytokine Storm Associated With COVID-19 Infectionhttps://modernod.com/news/astrazeneca-to-study-btk-inhibitor-calquence-as-treatment-for-cytokine-storm-associated-with-covid-19-infection/2477575/AstraZeneca announced that it will investigate the potential of the BTK inhibitor Calquence (acalabrutinib) in the treatment of the cytokine storm associated with COVID-19 infection in severely ill patients. The company noted that the design of the CALAVI study is based on “strong scientifi